Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060333 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
A Phase 2 study of Recurrent Melanoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 20
- Study locations
NCT00060333: Completed Phase 2 study of Recurrent Melanoma, sponsored by Alliance for Clinical Trials in Oncology.
NCT00060333 is a Phase 2 study of Recurrent Melanoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 20 participants, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060333, a Phase 2 study of Recurrent Melanoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying how well adjuvant radiation therapy works in treating patients who have undergone surgery for desmoplastic melanoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surgery.
Primary Outcome
The primary endpoint is the incidence of local recurrence within 2 years after treatment. Local recurrence (LR) is defined as a desmoplastic melanoma lesion recurring within the radiated field. The properties of the binomial distribution will be used to construct a 95% confidence interval for the true 2-year local recurrence rate (LRR). The Kaplan-Meier method will be used if some patients are lost to follow-up.
Conditions Studied
Interventions
- RADIATION radiation therapy
Study Locations (20)
Iowa
- Mercy Capitol Hospital - Des Moines
- CCOP - Iowa Oncology Research Association - Des Moines
- John Stoddard Cancer Center at Iowa Methodist Medical Center - Des Moines
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center - Des Moines
- Medical Oncology and Hematology Associates at Mercy Cancer Center - Des Moines
- Mercy Cancer Center at Mercy Medical Center - Des Moines - Des Moines
- John Stoddard Cancer Center at Iowa Lutheran Hospital - Des Moines
- McCreery Cancer Center at Ottumwa Regional - Ottumwa
- Siouxland Hematology-Oncology Associates, LLP - Sioux City
- Mercy Medical Center - Sioux City - Sioux City
- St. Luke's Regional Medical Center - Sioux City
Minnesota
- Fairview Ridges Hospital - Burnsville
- Mercy and Unity Cancer Center at Mercy Hospital - Coon Rapids
- Fairview Southdale Hospital - Edina
- Mercy and Unity Cancer Center at Unity Hospital - Fridley
- Minnesota Oncology Hematology, PA - Maplewood - Maplewood
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital - Minneapolis
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Illinois
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
What the finished NCT00060333 record still lists
NCT00060333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Recurrent Melanoma appearing as the primary indexed condition, and to 1 intervention - of which radiation therapy is the first listed.
NCT00060333 names 20 study sites across 5 states, led by Iowa, Minnesota, Arizona.
Frequently Asked Questions
What is clinical trial NCT00060333 about?
NCT00060333 is a clinical study titled "Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma". This phase II trial is studying how well adjuvant radiation therapy works in treating patients who have undergone surgery for desmoplastic melanoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surger...
What is the current status of trial NCT00060333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-07. Estimated completion is 2016-04.
What conditions does trial NCT00060333 study?
This clinical trial studies the following conditions: Recurrent Melanoma.
What interventions are being tested in trial NCT00060333?
The interventions under investigation include: radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00060333?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00060333 being conducted?
This trial has 20 study locations across Arizona, Florida, Illinois, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00060333's enrollment target sits among peer trials
20 22nd of 23 higher than 2 of 23 other Recurrent Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia